NCT03228043 is a NA clinical trial of Apatinib in Apatinib, sponsored by Nanchong Central Hospital.

Who is sponsoring NCT03228043?

NCT03228043 is sponsored by Nanchong Central Hospital.

What drugs are being tested in NCT03228043?

Interventions in NCT03228043: Apatinib, CAPEOX.

What condition does NCT03228043 study?

NCT03228043 studies Apatinib, Outcome, Fatal, Colorectal Cancer, Surgery, Adjuvant Chemotherapy.

Is NCT03228043 still recruiting?

NCT03228043 is currently withdrawn. Last updated 14 November 2024.

Last reviewed 2024-11-14 · How we verify

NCT03228043

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Apatinib for Resectable Colorectal Cancer

Withdrawn NA Last updated 14 November 2024

What this trial tests

NA trial testing Apatinib in Apatinib. Withdrawn.

Timeline

1 March 2020

Primary endpoint
1 March 2021

1 March 2023

Quick facts

Lead sponsor	Nanchong Central Hospital
Phase	NA
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Start date	1 March 2020
Primary completion	1 March 2021
Estimated completion	1 March 2023
Sites	1 location across China

Drugs / interventions tested

Apatinib (Apatinib) — full drug profile →
CAPEOX — full drug profile →

Conditions studied

Apatinib — all drugs for Apatinib →
Outcome, Fatal — all drugs for Outcome, Fatal →
Colorectal Cancer — all drugs for Colorectal Cancer →
Surgery — all drugs for Surgery →

Sponsor

Nanchong Central Hospital

Who can join

Adults 18 to 75, any sex, with Apatinib or Outcome, Fatal. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Objective: To compare the outcome of patients with colorectal cancer who treated with adjuvant therapy or Apatinib with adjuvant therapy postoperatively. Language: English.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Apatinib

Trials testing the same drug.

NCT07309419 — A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunothera · Phase 2, PHASE3 · not yet recruiting
NCT07334483 — A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC · Phase 2 · recruiting
NCT07031154 — A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Rese · Phase 2 · not yet recruiting
NCT07294664 — PD1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer · Phase 2 · recruiting
NCT06893887 — Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma · NA · recruiting

Other recruiting trials for Apatinib

Currently open trials in the same condition.

NCT06485466 — TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma · Phase 3 · recruiting
NCT05512481 — Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma · Phase 2 · recruiting

Other Nanchong Central Hospital trials

Trials by the same sponsor.

NCT07208786 — Pre-emptive Endoscopic Vacuum Therapy Reduces the Incidence of Anastomotic Leakage After Colorectal Cancer Surgery · NA · recruiting
NCT06865638 — Efficacy and Safety of Colorectal Anastomotic Leak Testing · NA · recruiting
NCT06885788 — Uterine Round Ligament Preservation Vs Resection in Laparoscopic Inguinal Hernia Repair in Women：A Multicenter,Stratifie · NA · recruiting
NCT06879860 — The Impact of 3D Patch One-Suture Fixation vs No Fixation on Chronic Pain and Recurrence in Ⅲ Inguinal Hernia · NA · enrolling by invitation
NCT06869096 — Chlorhexidine Gluconate Versus Saline for Flushing the Surgical Area During Colorectal Cancer Surgery · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03228043 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nanchong Central Hospital
Last refreshed: 14 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03228043.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing